WILLIAM EDGELL: Open Payments
NPI 1356019319 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,527 in 69 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $1,479 · 2025 $1,527
Food & beverage: $1,467Education: $60
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $314 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $197 |
| AstraZeneca Pharmaceuticals LP | 8 | $172 |
| Astellas Pharma US Inc | 6 | $145 |
| Exact Sciences Corporation | 4 | $88 |
| Aimmune Therapeutics, Inc. | 4 | $88 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Phathom Pharmaceuticals, Inc. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Lilly USA, LLC | 3 | $56 |
Products named: CAPLYTA, QULIPTA, UBRELVY, AIRSUPRA, The Cologuard Plus Collection Kit, ZENPEP, Veozah, GEMTESA.
Industry payments across OR — which companies pay providers there.
